April 8, 2016 / 4:16 PM / a year ago

BRIEF-Eli Lilly, AstraZeneca announce continuation of clinical trial for AMARANTH

April 8 (Reuters) - Eli Lilly And Co :

* Eli Lilly and Company and AstraZeneca announce continuation of pivotal clinical trial for people with early Alzheimer’s disease

* AMARANTH, in development as potential treatment for early alzheimer’s disease, to continue to Phase 3 of Phase 2/3 seamless trial

* Says AstraZeneca will receive a milestone payment from Lilly now that AZDd3293 has moved into Phase 3 testing

* Says payment will result in Q2 charge of $100 million (pre-tax) to Lilly’s GAAP and non-GAAP research and development expense

* Says Lilly and AstraZeneca have also announced planned initiation of a new Phase 3 trial for AZD3293

* Says DAYBREAK will begin enrolling participants in Q3 of 2016 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below